Follow-Up after Acute Pulmonary Embolism - a Prospective Observational Multicenter Cohort Study

Conditions

I26.9

Farmakis IT, Valerio L, Barco S, Hobohm L, Mohr K, Christodoulou KC, Dumitrescu D, Ewert R, Faehling M, Fistera D, Held M, Giannakoulas G, Lurz P, Rosenkranz S, Klok FA, Konstantinides SV.

2025-12-23

10.1016/j.jtha.2025.11.029

Functional capacity and dyspnea during follow-up after acute pulmonary embolism.

Farmakis IT, Valerio L, Barco S, Christodoulou KC, Ewert R, Giannakoulas G, Held M, Hobohm L, Keller K, Wilkens H, Rosenkranz S, Konstantinides SV.

2023-08-2911 citations

10.1016/j.jtha.2023.08.024

Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism: Analysis From a Prospective Multicenter Cohort Study.

Valerio L, Barco S, Jankowski M, Rosenkranz S, Lankeit M, Held M, Gerhardt F, Bruch L, Ewert R, Faehling M, Freise J, Ghofrani HA, Grünig E, Halank M, Hoeper MM, Klok FA, Leuchte HH, Mayer E, Meyer FJ, Neurohr C, Opitz C, Schmidt KH, Seyfarth HJ, Trudzinski F, Wachter R, Wilkens H, Wild PS, Konstantinides SV.

2021-02-0348 citations

10.1016/j.chest.2021.01.071

Interventions

Group 1: Patients with confirmed acute pulmonary embolism will be treated according to current guidleines and invited to control vists in the clinic after 3, 12 and 24 months where data, including the

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Objectively confirmed diagnosis of acute symptomatic PE by multidetector computed tomography (CT), pulmonary angiography, or V/Q lung scan according to established diagnostic criteria (1), with or without symptomatic deep vein thrombosis; 2) Ability of subject to understand character and individual consequences of participation in the study; 3) Written informed consent must be available before enrollment in the study; 4) Age =18 years

Exclusion criteria

Exclusion criteria: 1) Subjects unwilling or unable to sign the informed consent form; 2) Patients in whom the diagnosis of PE is an asymptomatic incidental finding during diagnostic workup for another disease; 3) Patients with previously diagnosed chronic thromboembolic pulmonary hypertension; 4) No subject will be allowed to enroll in this study more than once.

Design outcomes

Primary

Measure	Time frame
1) Confirmed diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) at any follow-up visit (at 3, 12 und 24 months) during 2 year-follow-up; 2) Post-PE impairment at =1 follow-up visit, defined by deterioration - compared to the previous visit or to the findings at discharge - by at least one category, or persistence of the greatest-severity category, in =1 of the echocardiographic parameters PLUS deterioration by at least one category or persistence of the greatest-severity category in =1 of the clinical, functional, or laboratory parameters.	—

Measure

Time frame

1) Confirmed diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) at any follow-up visit (at 3, 12 und 24 months) during 2 year-follow-up; 2) Post-PE impairment at =1 follow-up visit, defined by deterioration - compared to the previous visit or to the findings at discharge - by at least one category, or persistence of the greatest-severity category, in =1 of the echocardiographic parameters PLUS deterioration by at least one category or persistence of the greatest-severity category in =1 of the clinical, functional, or laboratory parameters.

—

Secondary

Measure	Time frame
Overall mortality, recurrent deep vene thrombosis od pulmonal embolism, stroke, functional impairment defined by oxygen comsumption during exercise test, 6-minute walkingtest and Borg's dyspnoea Index, echcardiographic evidence of pulmonal hypertension, changes in quality of life at 3, 12 and 24 months	—

Countries

Germany

Contacts

Public ContactStavros Konstantinides

Centrum für Thrombose und HämostaseUniversitätsmedizin der Johannes Gutenberg-Universität Mainz

sabrina.rump@unimedizin-mainz.de06131 17 8382

Outcome results

None listed